dupilumab + timothy grass pollen extract

**dupilumab + timothy grass pollen extract** is a combination therapy of a monoclonal antibody (dupilumab) and an allergen immunotherapy (timothy grass pollen extract) used experimentally for the treatment of grass pollen-induced seasonal allergic rhinitis. - **Dupilumab** is a fully human IgG4 monoclonal antibody that binds to the interleukin-4 receptor alpha (IL-4Rα), blocking signaling of both IL-4 and IL-13, key mediators of type 2 inflammatory response[1][3][6]. - **Timothy grass pollen extract** (Phleum pratense) is a standardized allergen used in subcutaneous (SCIT) or sublingual (SLIT) immunotherapy for grass pollen allergy[5][8]. The combination has been investigated in phase 2 studies, demonstrating improved tolerability for allergen immunotherapy but not significant improvement in symptom reduction compared to allergen immunotherapy alone[1][3][9]. This combination is under clinical investigation, not approved for marketing.

Brand names

Dupixent + Grazax

Other names

dupilumab + timothy grass SCITdupilumab + timothy grass SLITdupilumab + Phleum pratense extract